Src is a nonreceptor tyrosine kinase that coordinates responses to diverse soluble and adhesive signaling molecules and regulates cell proliferation, survival, differentiation and migration [1] . Normally, Src activity is tightly regulated, and Src-catalyzed phosphorylation is counterbalanced by phosphotyrosine phosphatases [2, 3] . However, deregulated mutant Src causes malignant transformation when highly expressed [4] . Src transformation is dose dependent, but it has been unclear how much mutant Src, compared with endogenous Src, is required for transformation [5] . Here, we show that transformation requires highlevel overexpression of mutant src mRNA, in part because active Src protein is degraded by ubiquitin-mediated proteolysis [6] . We show that active but not inactive Src protein is downregulated depending on the putative tumor suppressor and E3 ubiquitin ligase component, Cullin-5 (Cul5). Cul5 removal synergizes with physiological levels of mutant src mRNA to increase protein tyrosine phosphorylation, induce morphological transformation, and deregulate growth. Cul5 also represses Src-induced tumorigenesis and regulates Src signaling in normal cells. These results suggest that, when Src is activated by mutation or physiological mechanisms, its effects are limited by Cul5, which downregulates active Src and its phosphorylated substrates. These findings demonstrate the importance of a new mechanism that downregulates Src signaling in cells.
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Results and Discussion
We generated fibroblast cell lines in which wild-type or mutant mouse src genes were expressed at various levels. The mutants encode proteins SrcY529F (Src YF ), which lacks its C-terminal inhibitory Y529 and is fully active [7] , and SrcQ530* (Src Q* ), which is partially phosphorylated at Y529 because of truncation of six C-terminal amino acids and is partly active [8] . Src Q* also escapes regulation by PDZ-domain proteins binding to the Src C terminus [9] . To facilitate measurement of expression levels, we transduced the src genes into src 2/2 mouse embryo fibroblasts (MEFs) [10] , immortalized by the 3T3 protocol [11] , and the expression levels of ectopic src mRNA and Src protein were compared to the endogenous levels in src +/+ 3T3 MEFs. We define ''normal'' src mRNA or Src protein level as being equal to that in src +/+ MEFs and thus corresponds to expression from both genomic alleles.
We isolated polyclonal src 2/2 MEF cell lines with different expression levels of control Src WT and activated Src YF and Src Q* . Lines with 50%-100% of the normal level of src mRNA were designated WT= , YF=, and Q*= , whereas lines WT>, YF>, and Q*> overexpressed src mRNA 20-, 7-, and 9-fold, respectively ( Figure 1A and Figure S1 available online). Overexpressed mutants but not wild-type src caused extensive tyrosine phosphorylation of a wide range of cellular proteins, but had little effect when expressed at normal level ( Figure S2 ). Overexpressed mutants but not wild-type src also deregulated cell growth in monolayer and semisolid media cultures ( Figures 1B and 1C and Figure S3 ). However, cell lines YF= and Q*=, expressing mutant src at normal RNA level, were not transformed ( Figures 1B and 1C and Figure S3 ), suggesting that src must be overexpressed as well as mutationally activated for transformation.
Active Src protein is downregulated by the proteasome [6] , so mutant Src protein may be underexpressed even though its mRNA level is normal. We measured Src protein levels by using western blotting. Wild-type or mutant Src, overexpressed 7-to 20-fold as mRNA, was overexpressed 15-to 30-fold as protein ( Figure 1D and Figure S4 ). However, mutant YF or Q* Src protein, expressed at normal mRNA level, was <20% as abundant as the wild-type control ( Figures 1D and 1E ). This suggests that negative feedback by proteolysis might limit expression of, and transformation by, mutant Src and that the feedback mechanism may be overwhelmed when Src is overexpressed.
To investigate the importance of proteolysis in Src expression and transformation, we inhibited expression of selected ubiquitin E3 ligases that may target active Src or its substrates. We used retroviral small hairpin RNA (shRNA) to inhibit expression of either the ubiquitin E3 ligase Cbl or the E3 ligase component Cul5, both previously implicated in degradation of active SFKs [12] [13] [14] [15] or Src substrates [15] . The latter forms complexes with elongin B/C, Rbx2, and one of the suppressors of cytokine signaling (SOCS) proteins [16] [17] [18] . There are more than 20 SOCS proteins, of which seven contain an Src homology-2 (SH2) domain that allows them to bind to phosphotyrosine proteins [19] , possibly including active Src.
Knockdown of Cul5 but not Cbl greatly enhanced mutantSrc-protein expression to nearly the normal level (Figures 2B and 2C and Figure S5 ), but had no effect on wild-type Src (Figures 2A and 2C) . As a control, knockdown of Cullin-2 (Cul2) had no effect (data not shown). Importantly, knockdown of Cul5 did not increase src mRNA levels ( Figure 2D ). These results indicate that Cul5 regulates the level of activated mutant Src protein but not mRNA and does not affect inactive Src protein.
Cul5 also regulated the level of active wild-type Src. The absence of Csk from csk 2/2 cells activates endogenous Src [20] , which is rescued by re-expressing active Csk but not inactive CskR222 [21] . We found that removing Cul5, but not Cbl, increased the level of active Src in csk 2/2 or CskR222 cells, but did not affect the level of inactive Src in csk 2/2 cells re-expressing functional Csk ( Figure 2E and Figure S6 ). This suggests that Cul5 is the main E3 ligase that downregulates wild-type Src if it is activated by absence of Csk. Furthermore, we found that removing Cul5 enhanced both basal and *Correspondence: jcooper@fhcrc.org integrin-stimulated activity of wild-type Src ( Figure 2F ). These results show that Cul5 downregulates active endogenous Src protein. Consistent with the increased levels of activated mutant Src, we found that removing Cul5 induced partial transformation of YF= cells (Figure 3 ). Removing Cul5 but not Cbl or Cul2 relieved contact inhibition ( Figure 3A) , induced morphological transformation and subcellular redistribution of the Src substrate and focal adhesion protein paxillin (Figure 3B) , enhanced tyrosine phosphorylation of cellular substrates ( Figure S7B ), and inhibited cell spreading on tissue culture plastic ( Figure 3C ). Also, removing Cul5 stimulated the anchorageindependent growth of YF = cells ( Figure 3D and Figure S7 ).
Removing Cul5 had no detectable effects on WT= cells ( Figure 3D and Figure S7 ; data not shown), or on csk 2/2 cells in which Csk was re-expressed, but increased the transformation of csk 2/2 cells or csk 2/2 cells expressing inactive CskR222 ( Figure 3E ). However, Cul5 removal had no effect on Src protein levels ( Figure S8A ), tyrosine phosphorylation of cellular substrates (Figure S8B ), or transformation of cells ( Figure 3F ) that were partially transformed either by oncogenic K-Ras G12D and adenovirus E1A or by p53 deletion and E1A [22, 23] . These results indicate that Cul5 removal specifically stimulates transformation by Src that is activated by mutation or by absence of Csk but has little effect on cells transformed by E1A and cooperating oncogenes.
We tested the effect of Cul5 on Src-induced tumors, using xenograft assays in nude mice (Figures 4A-4E) . Removal of Cul5 from cells with wild-type Src induced tumors, but only after long latency (median 60 days, Figure 4A) . Mutant Src at a normal RNA level was also weakly tumorigenic (median latency 38 days), but the combination of Cul5 removal with mutant Src significantly increased incidence and decreased latency (median 20 days; p < 0.05 relative to either mutant Src alone or Cul5 knockdown alone). Tumors were readily ; E1A or p53 2/2 ; E1A MEFs infected with either vector or Cul5 0 shRNA were assayed for anchorage-independent growth. All data are representative of at least two independent assays and data represented in (A) and (D)-(F) are the mean 6 SD from three independent samples per cell line.
detected with ultrasound or visually ( Figures 4B and 4C ). The increase in tumor volume over time showed a trend that reflected tumor latency ( Figure 4D ). Tumors were also induced by highly overexpressed mutant Src, and these tumors were highly vascularized hemangiosarcomas ( Figure 4E , top panels), as expected [24, 25] . However, tumors induced by low levels of mutant Src, with or without Cul5 knockdown, were less vascular fibrosarcomas or rhabdomysarcomas. Therefore, expression of mutant src mRNA at endogenous level synergizes with Cul5 removal for tumor induction, and these tumors are qualitatively different from those induced by high levels of mutant Src. This suggests that Cul5 may oppose specific Src-dependent signaling pathways.
We wondered whether Cul5 opposes Src transformation solely by downregulating Src or whether it may also destabilize other transformation-related proteins. Some SFK substrates have been identified as targets of SOCS-Cul5 complexes [15, 17, 26] . We reasoned that, if Cul5 destabilizes Src alone, then expressing mutant Src at normal protein level should induce transformation, even if Cul5 is present.
To test this, we made clones of cells with different levels of Src expression. As shown in Figures S9A-S9C , overexpression of mutant src mRNA approximately 3-fold allowed mutant Src protein to be made at near-normal level (clones YF16 and Q*10), but there was little change in protein tyrosine phosphorylation ( Figure S9D ) and the cells were not transformed ( Figure S9E ). Approximately eight-fold overexpression of mutant Src protein allowed partial transformation (clones YF6 and Q*9, Figure S9 ). Therefore, transformation caused by removal of Cul5 from cells with endogenous levels of mutant src mRNA is not simply due to the increased level of mutant Src protein.
Cul5 must have other effects important for transformation by active Src but not by other oncogenes like E1A ( Figure 3F ). Because Cul5 complexes with certain SOCS proteins can recognize tyrosine-phosphorylated targets [19] , it seems likely that Cul5 also downregulates phosphorylated Src substrates.
Consistent with this concept, a preliminary phosphoproteomics screen suggested that levels of the Src substrate Dok1, a cytoplasmic protein implicated in negative regulation of Src [27, 28] , may be increased when Cul5 is removed from cells expressing low levels of activated Src (Supplemental Experimental Procedures). Indeed, western blotting showed an increase in Dok1-protein level in YF= cells lacking Cul5 (Figures 4F and 4G) . When Dok1-protein levels were adjusted for Src-induced increase in dok1 mRNA, it appears that active Src causes a decrease in Dok1 protein and that this decrease requires Cul5 (Figures S10A and S10B) . Although the relevance of Dok1 for Src-mediated transformation is unknown, Dok1 is a candidate for a Src substrate that may be targeted for degradation by Cul5.
Taken together, these results suggest that Cul5 opposes Src transformation by downregulating both active Src and proteins it has phosphorylated ( Figure 4H ). Cul5 is presumably acting in a complex with one or more SOCS proteins that contain SH2 domains through which they bind to tyrosinephosphorylated substrates. There are seven such SOCS proteins [19] , and we have detected at least two (SOCS1 and SOCS3) in the cells studied here, so there may be functional redundancy. Interestingly, however, many SOCS proteins are induced by mitogens or transformation [17] , in some cases via Src [29, 30] . This suggests a negative-feedback loop in which Src activity stimulates expression of SOCS proteins, which then bind to active Src and its substrates and target them for ubiquitination by Cul5 and subsequent degradation. This mechanism may have evolved to fine-tune Src activity in response to physiological stimuli.
The weak oncogenic activity of mutant src resembles that of H-ras-1, which is infrequently mutated in human cancers and only causes frank transformation when overexpressed [31] [32] [33] , and contrasts with K-ras, which is commonly mutated in human cancers and causes malignancy in animals without overexpression [22, 33] . Consistent with this, src is commonly overexpressed but only very infrequently mutated in human cancers [8, [34] [35] [36] . One possibility is that mutant src would require a cooperating genetic change, such as loss of cul5. The cul5 gene maps to a region (11q22-23) that undergoes loss of heterozygosity (LOH) in many cancers [37] . cul5 mRNA is underexpressed in a substantial fraction of poor-prognosis breast cancers and neuroblastomas [38, 39] , and Cul5 overexpression inhibits estrogen-dependent and -independent growth of the breast-cancer cell line T47D [40] . Thus, Cul5 may be a tumor suppressor, and its suppressive effects may be in part due to its ability to inhibit Src.
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